Metrics to compare | PALI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPALIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −1.7x | −0.2x | |
PEG Ratio | −0.04 | −0.10 | 0.00 | |
Price/Book | 1.6x | 2.1x | 2.6x | |
Price / LTM Sales | 348.9x | 65.9x | 2.7x | |
Upside (Analyst Target) | - | 140.9% | 69.6% | |
Fair Value Upside | Unlock | 5.8% | 11.7% | Unlock |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.